{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:08:12Z","timestamp":1775592492870,"version":"3.50.1"},"reference-count":20,"publisher":"Scientific Scholar","content-domain":{"domain":["indianjnephrol.org"],"crossmark-restriction":true},"short-container-title":["Indian J Nephrol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has recently evolved beyond cancer therapy\u2019s boundary to treating autoimmune diseases such as lupus nephritis. In CAR T-cell therapy, the genetically engineered patient\u2019s T cells express a receptor specifically targeting antigens such as CD19, a protein found on the surface of B cells. By directing the immune system to eliminate B cells, which play a central role in the pathogenesis of systemic lupus erythematosus, CAR T-cell therapy offers a novel and potent approach to resetting the immune system and achieving remission in difficult-to-treat lupus nephritis patients and many such conditions in nephrologists\u2019 practice.<\/jats:p>","DOI":"10.25259\/ijn_274_2024","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T12:20:59Z","timestamp":1733919659000},"page":"456-459","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nephrology\u2019s Next Frontier: Expanding the Reach of CAR T-Cell Therapy for Refractory Lupus Nephritis and Beyond"],"prefix":"10.25259","volume":"35","author":[{"given":"Jeyakumar","family":"Meyyappan","sequence":"first","affiliation":[{"name":"Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayan","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"10.25259\/IJN_274_2024\/ref-1","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","article-title":"Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: A systematic review and meta-analysis","volume":"42","author":"Fatoye","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.25259\/IJN_274_2024\/ref-2","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.25259\/IJN_274_2024\/ref-3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","volume":"25","author":"Ambrose","year":"2016","journal-title":"Lupus"},{"key":"10.25259\/IJN_274_2024\/ref-4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group, et al","year":"2024","journal-title":"Kidney Int"},{"key":"10.25259\/IJN_274_2024\/ref-5","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.25259\/IJN_274_2024\/ref-6","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1681\/ASN.2016040415","article-title":"Current and emerging therapies for lupus nephritis","volume":"27","author":"Parikh","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.25259\/IJN_274_2024\/ref-7","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s12094-023-03122-8","article-title":"Chimeric antigen receptor T cells therapy in solid tumors","volume":"25","author":"Rababah","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.25259\/IJN_274_2024\/ref-8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.25259\/IJN_274_2024\/ref-9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.25259\/IJN_274_2024\/ref-10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.25259\/IJN_274_2024\/ref-11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/IJN_274_2024\/ref-12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.25259\/IJN_274_2024\/ref-13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.25259\/IJN_274_2024\/ref-14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.6004\/jadpro.2019.10.4.11","article-title":"CAR T-cell therapy: Adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol."},{"key":"10.25259\/IJN_274_2024\/ref-15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.25259\/IJN_274_2024\/ref-16","doi-asserted-by":"publisher","first-page":"829.e1","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.25259\/IJN_274_2024\/ref-17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.kint.2024.02.008","article-title":"CAR T-cell therapy-paving the way for sensitized kidney transplant patients","volume":"105","author":"Jarmi","year":"2024","journal-title":"Kidney Int"},{"key":"10.25259\/IJN_274_2024\/ref-18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaccao.2022.09.002","article-title":"Successful CAR T cell therapy in a heart and kidney transplant recipient with refractory PTLD","volume":"4","author":"Oren","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.25259\/IJN_274_2024\/ref-19","doi-asserted-by":"publisher","first-page":"e1584","DOI":"10.1097\/TXD.0000000000001584","article-title":"CAR T-cell therapy for refractory posttransplantation lymphoproliferative disorder in a kidney transplant patient","volume":"10","author":"Guy","year":"2024","journal-title":"Transplant Direct"},{"key":"10.25259\/IJN_274_2024\/ref-20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000536194","article-title":"CAR-T cell therapy: Advances in kidney-related diseases","volume":"10","author":"Wu","year":"2024","journal-title":"Kidney Dis (Basel)"}],"container-title":["Indian Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/indianjnephrol.org\/nephrologys-next-frontier-expanding-the-reach-of-car-t-cell-therapy-for-refractory-lupus-nephritis-and-beyond\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/indianjnephrol.org\/nephrologys-next-frontier-expanding-the-reach-of-car-t-cell-therapy-for-refractory-lupus-nephritis-and-beyond\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:22:49Z","timestamp":1751300569000},"score":1,"resource":{"primary":{"URL":"https:\/\/indianjnephrol.org\/nephrologys-next-frontier-expanding-the-reach-of-car-t-cell-therapy-for-refractory-lupus-nephritis-and-beyond\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":20,"alternative-id":["10.25259\/IJN_274_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijn_274_2024","relation":{},"ISSN":["1998-3662","0971-4065"],"issn-type":[{"value":"1998-3662","type":"electronic"},{"value":"0971-4065","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"article-number":"456"}}